Paper Details

  1. Home
  2. Paper Details

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.

Author: , Campo-MoneoEsther, GarcíaFederico, García-FraileLucio, González-SernaAlejandro, GranadosRafael, MacíasJuan, MerinoDolores, MoranoLuis E, PinedaJuan A, RealLuis M, TéllezFrancisco, Vera-MendezFrancisco, de Los SantosIgnacio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elbasvir/grazoprevir (EBR/GZR) achieved high sustained virological response (SVR) rates in people who inject drugs (PWID) with and without opioid agonist therapy (OAT) in real-world conditions. However, recent drug users had lower SVR rates.
Paper Details　
Original Abstract of the Article :
Elbasvir/grazoprevir (EBR/GZR) use in drug users on opiate agonist therapy (OAT) is supported by the C-EDGE Co-STAR trial. SVR rates in this study were within those found in the rest of patients included by the EBR/GZR development programme. In clinical practice, however, efficacy could theoreticall...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.13496

データ提供：米国国立医学図書館（NLM）

Elbasvir/Grazoprevir: Navigating the HCV Desert for Opioid Users

The fight against hepatitis C virus (HCV) infection, like a long and arduous camel trek, demands effective treatments. This study explores the effectiveness of elbasvir/grazoprevir (EBR/GZR) in treating HCV-infected individuals who are on opioid agonist therapy (OAT). It's a challenging terrain, as OAT can complicate the treatment process.

EBR/GZR: A Hopeful Oasis for Opioid Users with HCV

The study found that EBR/GZR achieved high sustained virologic response (SVR) rates in HCV-infected individuals, both those on and off OAT. However, individuals who had recently used drugs showed significantly lower SVR rates, highlighting the need for tailored approaches in this patient group.

Understanding the Terrain: A Camel's Perspective

This study sheds light on the importance of considering recent drug use in the treatment of HCV-infected individuals on OAT. It underscores the need to address individual challenges and develop strategies to improve treatment outcomes in this population. It's a reminder that the HCV desert can be navigated, but with a careful understanding of the terrain and the needs of those traveling through it.

Dr. Camel's Conclusion

This research offers a valuable roadmap for navigating the complex treatment landscape of HCV infection among opioid users. It underscores the need for tailored strategies and continued research to ensure that everyone has access to effective treatment and a chance to reach the oasis of viral suppression.

Date :
  1. Date Completed 2021-10-01
  2. Date Revised 2022-09-09
Further Info :

Pubmed ID

33721377

DOI: Digital Object Identifier

10.1111/jvh.13496

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.